Dr. Nordquist is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
7710 Mercy Rd
Ste 122
Omaha, NE 68124Phone+1 402-393-3110Fax+1 402-393-4499
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
- University of South Florida MorsaniResidency, Internal Medicine, 1998 - 2001
- Creighton University School of MedicineClass of 1998
Certifications & Licensure
- NE State Medical License 2003 - 2026
- NY State Medical License 2000 - 2005
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2011-2013
- QOPI Certification ASCO
Clinical Trials
- A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer Start of enrollment: 2012 Dec 01
- A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Start of enrollment: 2011 Dec 01
- Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis Start of enrollment: 2014 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 924 citationsLutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.Oliver Sartor, Johann S. de Bono, Kim N. Chi, Karim Fizazi, Ken Herrmann
The New England Journal of Medicine. 2021-06-23 - 4 citationsDeep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patient...Fred Saad, Maha H A Hussain, Bertrand Tombal, Karim Fizazi, Cora N Sternberg
European Urology. 2024-10-01 - 183 citationsRandomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate CancerHoward I. Scher, Xiaoyu Jia, Kim N. Chi, Ronald de Wit, William R. Berry
Journal of Clinical Oncology. 2011-06-01
Journal Articles
- Phase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate CancerMark T Fleming, Luke T Nordquist, William R Berry, Clinical Cancer Research
Press Mentions
- Clarity Completes First Stage of Prostate Cancer TrialMay 25th, 2023
- Clarity's Theranostic Prostate Cancer Trial Advances to Cohort 2May 24th, 2023
- First Patient Treated in Clarity's Therapeutic Prostate Cancer TrialOctober 7th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: